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Abstract Nitric oxide (NO) reversibly inhibits mitochondrial 
respiration by competing with oxygen at cytochrome oxidase. 
Concentrations of NO measured in a range of biological systems 
are similar to those shown to inhibit cytochrome oxidase and 
mitochondrial respiration. Inhibition of NO synthesis results in 
a stimulation of respiration in a number of systems. It is proposed 
that NO exerts some of its main physiological and pathological 
effects on cell functions by inhibiting cytochrome oxidase. Fur- 
ther NO may be a physiological regulator of the affinity of 
mitochondrial respiration for oxygen, enabling mitochondria to 
act as sensors of oxygen over the physiological range. 
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1. Introduction 
Nitric oxide (NO) has a number of physiological roles, in- 
cluding: (a) relaxation of smooth muscle; (b) neurotransmission 
and neuromodulation; (c) inhibition of platelet aggregation and 
adhesion; and (d) killing of pathogens (reviewed in [1-5]). NO 
can also be toxic to host cells, and has been implicated in variety 
of pathological processes. NO is known to be produced by a 
several isoforms of nitric oxide synthase, but the effector system 
by which NO exerts its effects on cells is less clear. The prime 
candidate for NO's effector system has been guanyl cyclase, 
since NO binds to and stimulates guanyl cyclase and thus might 
control cell functions via cGMP and the cGMP-dependent pro- 
tein kinase. However, the evidence that guanyl cyclase mediates 
responses to NO is relatively indirect. I suggest here that some 
of the major physiological nd pathological effects of NO are 
mediated via its inhibition of cytochrome oxidase, and thus of 
cellular ATP production (see Fig. 1). 
Nitric oxide has been known to bind to cytochrome oxidase 
for about 20 years, and has been used as an experimental tool 
for investigating the spectra and mechanism of cytochrome 
oxidase [6]. However, its potential as a regulator of respiration 
was not investigated, asNO was not known to be a physiolog- 
ical mediator until about 5 years ago. Recently it has been 
found that NO rapidly and reversibly inhibits the steady-state 
turnover of isolated cytochrome oxidase at sub-micromolar 
concentrations of NO [7]. The inhibition has also been seen as 
a reversible inhibition of respiration in isolated submitochon- 
drial particles [8], mitochondria [9], brain nerve terminals [7], 
*Corresponding author. Fax: (44) (1223) 33-3345. 
cultured astrocytes [10], muscle slices [11,12], and as a reversible 
decrease in mitochondrial membrane potential in isolated mito- 
chondria [13] and cells [14] (see Table 1). The inhibition of 
cytochrome oxidase is competitive with oxygen [7], and NO 
binds with high affinity to the oxygen binding site of cyto- 
chrome oxidase when this site is reduced [6]. 
Inhibition of cytochrome oxidase will cause decreased ATP 
production, and thus increased cellular levels of ADP, AMP, 
GDP and Pi. The levels of these metabolites regulate a large 
range of cellular processes, including muscle contraction, pro- 
tein synthesis and ion transport [15], and thus inhibitors of 
cytochrome oxidase potentially regulate these processes. How- 
ever, strong, long-term inhibition of cytochrome oxidase is 
toxic to cells which cannot activate glycolytic ATP production 
sufficiently to supply essential ATP requiring reactions; and 
indeed continuous high levels of NO are toxic to many cells (see 
below). On the other hand, NO inhibition of cytochrome oxi- 
dase may be self-limiting because: (a) inhibition of cytochrome 
oxidase, which consumes most of the oxygen in the body, will 
raise tissue oxygen levels, which will both compete with NO at 
cytochrome oxidase and promote NO breakdown; and (b) cyto- 
chrome oxidase itself may catalyse NO breakdown [6]. 
Because NO competes with oxygen at cytochrome oxidase, 
NO raises the apparent Km of cytochrome oxidase for oxygen, 
potentially making mitochondrial respiration sensitive to oxy- 
gen concentration over the physiological range. A variety of 
evidence indicates that the apparent Km (Ka) for oxygen of 
respiration is much greater in intact tissues and cells (>1/IM) 
than in isolated mitochondria and isolated cytochrome oxidase 
(<1 /IM) [16,17]. A number of explanations of these findings 
have been suggested including macroscopic and microscopic 
diffusion gradients. But another possible xplanation is a com- 
petitive inhibitor of cytochrome oxidase (e.g. NO) which is 
present in the intact systems but not the isolated systems. A 
number of tissues (e.g. the vasculature and carotid body) are 
able to sense physiological changes in oxygen concentration, 
but the mechanism of oxygen sensing is unclear. The presence 
of NO in these tissues would enable cytochrome oxidase to act 
as an effective oxygen sensor, and I suggest hat NO may be 
an important physiological regulator of mitochondrial respira- 
tion, via adjusting the Km of cytochrome oxidase for oxygen. 
2. Quantitative assessment of the feasibility of NO regulation of 
respiration in vivo 
In this section I will try to make some quantitative assess- 
ment of: (a) whether an inhibitor of cytochrome oxidase could 
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Fig. 1. Scheme illustrating the hypothesis that NO exerts physiological and cytotoxic effects via inhibiting cytochrome oxidase within oxidative 
phosphorylation, resulting in a rise in cellular ADP and P~ levels, which in turn inhibits many cellular ATP-utilising processes. 
regulate mitochondrial respiration and ATP turnover; (b) the 
levels of NO found to inhibit cytochrome oxidase and respira- 
tion; (c) the levels of NO produced in physiological systems; 
and (d) whether stimulation of NO production does in fact 
inhibit respiration. 
Cytochrome oxidase is the terminal complex of the mito- 
chondrial electron transport chain, and is responsible for virtu- 
ally all the oxygen consumption of tissues. It is the only compo- 
nent of oxidative phosphorylation k own to operate far from 
equilibrium, and thus has often been considered as a potential 
site for regulation of mitochondrial ATP synthesis [15]. Cyto- 
chrome oxidase has been measured to have significant control 
over respiration i  isolated mitochondria (control coefficient of 
0.17 over state 3 respiration i isolated liver mitochondria [18]), 
indicating that inhibition of cytochrome oxidase will in fact 
inhibit mitocbondrial respiration at least in isolated mitochon- 
dria. Inhibitors of cytochrome oxidase or other components of 
oxidative phosphorylation can cause reversible inhibitions of 
multiple cell functions, such as muscle contraction, protein 
synthesis, ion transport, or neurotransmitter release [15,19]. 
Oxygen concentration appears to limit respiration in some tis- 
sues [15 17], suggesting that cytochrome oxidase is also limit- 
ing, and thus an agent (such as NO) that decreased the affinity 
of cytochrome oxidase for oxygen should inhibit respiration. 
Are the concentrations of NO found to inhibit cytochrome 
oxidase and respiration comparable to the concentrations of
NO produced in physiological systems? The concentration of 
NO required to half inhibit respiration in synaptosomes was 
270 nM at around 145 #M 02 (roughly the arterial concentra- 
tion of oxygen) and 60 nM NO at around 30 #M 02 (roughly 
the tissue level of 02). Similar levels of NO are required to 
inhibit respiration in isolated cytochrome oxidase and cells 
(Table 1). Endogenous levels of NO measured in various sys- 
Table 1 
Systems where NO has been shown to inhibit respiration 




Cytochrome oxidase (isolated) [7] 
Paracoccus cells and vesicles [8] 
Submitochondrial p rticles [8] 
Brain nerve terminals (isolated) [7] 
Mitochondria (isolated) [9] 
Astrocytes (cultured) [10] 
Muscle (isolated) [11,12] 
Exogenous NO was added and levels of NO required to half inhibit 
respiration are indicated, unless not known (-). Note that inhibition is 
oxygen dependent. 
tems range from 0.01 to 5 #M, with 0.1 to 1.0 #M NO being 
common after stimulation (Table 2). Thus it would appear that 
in some of these systems the level of NO is sufficient o cause 
significant and even substantial inhibition of cytochrome oxi- 
dase (depending on the oxygen concentration). 
Is there any direct evidence that stimulation of NO produc- 
tion causes inhibition of respiration, while inhibition of NO 
production causes timulation of respiration in a physiological 
system? In vascular smooth muscle cytokines have been shown 
to induce NO synthase resulting in inhibition of mitochondrial 
respiration [28]. In the hindlimb of anaesthetized dogs inhibi- 
tion of NO synthase resulted in a 40% increase in oxygen 
consumption of the limb despite a decrease in blood flow [29]. 
In conscious dogs inhibition of NO synthase resulted in a im- 
mediate 25% increase in whole body oxygen consumption, 
prompting the suggestion that endothelial NO tonically inhibits 
tissue respiration [30]. In isolated skeletal and heart muscle, 
bradykinin (which causes NO release from the endothelium) 
caused inhibition of tissue respiration, and the respiratory inhi- 
bition was reversed by inhibiting NO synthase [11,12]. In cul- 
tured astrocytes induction of NO synthase with interferon-?" 
and endotoxin caused the cells to produce 0.4-1.0#M NO and 
resulted in a 45% inhibition of respiration at high oxygen con- 
centrations and 80% at low oxygen concentrations [10]. The 
inhibition was immediately reversed when either NO synthase 
was inhibited or the NO was bound with haemoglobin. The 
inhibition was attributed to cytochrome oxidase on the basis 
of the substrate, oxygen and NO sensitivity [10]. Thus in these 
systems there is direct evidence that NO is involved in regulat- 
ing cellular espiration. In the following sections 1 will discuss 
the potential roles for NO inhibition of cytochrome oxidase in 
a variety of different systems. 
3. Smooth and striated muscle 
NO first came to prominence when it was found to be iden- 
tical with the endothelium-derived r laxing factor, responsible 
for relaxing vascular smooth muscle in response to ace- 
tylcholine and other agents in the lumen of blood vessels [5]. 
NO is produced by endothelial cells in response to these agents, 
and diffuses to the surrounding smooth muscle, where it causes 
relaxation and thus dilation of the vessel. The mechanism by 
which NO causes relaxation of smooth muscle is unclear, al- 
though it is generally assumed to act via guanyl cyclase, Could 
NO inhibition of cytochrome oxidase in the smooth muscle 
cause the relaxation? 
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Table 2 
Levels of NO produced in various biological systems in 
stimulants 
response to 
[NO] (uM) System Stimulus Ref. 
0.45 5.0 Endothelium in aorta Bradykinin 
0.13-0.85 Smooth muscle in aorta Bradykinin 
0.05-5.0 Endothelium (cultured) Bradykinin 
1.0-5.0 Platelets (isolated) Collagen 
0.02-0.14 Blood (fresh whole) Collagen 
0.01-0.08 Brain slice Electrical 
1.0-4.0 Brain (in vivo) Ischaemia 
0.4-1.0 Astrocytes (cultured) l-y + LPS 










l-y + LPS is Interferon-), and endotoxin. 
Endothelial cells produce anything from 0.05 to 5 pM NO 
in response to vascular elaxing agents, for example bradykinin 
[2~23]. Electrodes inserted into smooth muscle cells of the 
aorta record a NO level of 130-850 nM in response to bradyki- 
nin [20,21]. Exogenous addition of between 10 nm and 10 pM 
NO causes mooth muscle relaxation. These levels of NO are 
sufficient o cause a significant inhibition of cytochrome oxi- 
dase, the actual inhibition depending on the tissue oxygen con- 
centration. Such inhibition of cytochrome oxidase would lead 
to a rise in cellular ADP and Pi, which may inhibit the actino- 
myosin-ATPase [15], and thus potentially cause muscle relaxa- 
tion. 
Such a mechanism would also provide a simple explanation 
of how local oxygen concentration controls dilation of blood 
vessels. Decreased oxygen concentrations cause blood vessels 
to dilate, and the mechanism of this dilation is unclear [31]. If 
the vascular tone is set by NO inhibition of cytochrome oxidase 
in vascular smooth muscle, as suggested above, then a decrease 
in oxygen concentration would automatically cause dilation, 
due both to decreased competition of oxygen with NO at cyto- 
chrome oxidase, and decreased breakdown of NO by oxygen 
and oxyhaemoglobin. 
NO is thought o regulate relaxation in other smooth muscle 
types, for example, the stomach and intestine, and possibly 
lungs, bladder and uterus. Thus the occurrence and role of the 
NO-inhibition of respiration should be considered in these tis- 
sues. 
Recently NO synthase has been found in type 1I fibres of 
skeletal muscle, and inhibition of NO synthase promotes mus- 
cle contraction of isolated muscle bundles [32]. This has led to 
the suggestion that NO may have some role in promoting relax- 
ation in skeletal muscle. Again NO inhibition of cytochrome 
oxidase might be involved, since decreasing oxygen concentra- 
tion is well known to decrease skeletal muscle contraction. 
However, the levels of NO involved in physiological control of 
skeletal muscle contraction are not known. 
Resting skeletal muscle is the main heat producing organ in 
many small mammals, and resting muscle heat production or 
oxygen consumption may be controlled by noradrenaline and 
other vasoactive agents, via actions on the endothelium [33]. 
Perfusion of skeletal muscle with NO-producing agents causes 
an inhibition of oxygen consumption and thus heat production 
[33]. The respiration of isolated skeletal and heart muscle is 
inhibited by bradykinin (a stimulant of NO production from 
the endothelium) and the inhibition of respiration is prevented 
by inhibitors of NO synthase [11,12]. Inhibitors of NO synthase 
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stimulate oxygen consumption of canine hindlimb [29] and the 
whole body [30]. Thus it has been proposed that vascular NO 
production controls tissue respiration [29,30], and the likely site 
of action of NO is cytochrome oxidase. 
4. Brain and synapse 
NO has been implicated in mediating long-term potentiation 
and long-term depression i the central nervous ystem; that is 
changes in efficiency of synapses due to usage which may be 
important in memory formation [4]. Levels of NO measured 
during induction of long-term depression in cerebellar slices 
were 20-75 nM [26]. The mechanism by which NO might 
change synaptic efficiency is unknown. It seems unlikely that 
the acute effect of NO on cytochrome oxidase could be involved 
in these changes since the inhibition of respiration in nerve 
terminals and astrocytes i rapidly reversible [7,10] while the 
changes in synaptic efficiency are longer term. It seems more 
likely that the NO inhibition of cytochrome oxidase would 
cause a acute depression of synaptic activity, since anoxia or 
respiratory inhibition causes rapid inhibition of action-poten- 
tial-dependent glutamate release from isolated nerve terminals 
[19]. Indeed it has been reported that NO mediates an acute 
synaptic suppression at developing neuromuscular synapses, 
which was suggested to be involved in synaptic plasticity and 
possibly muscle fatigue [34]. NO has been reported to mediate 
growth arrest of cultured PC12 cells differentiating into neu- 
rons in response to nerve growth factor [35]; again the inhibi- 
tion of growth and DNA synthesis might be mediated by an 
inhibition of ATP production. 
Local changes in blood flow and metabolism occur within the 
brain in response to functional activation, e.g. visual stimula- 
tion [2]. The mediator between functional activation of neurons 
and increased blood flow is now thought o be NO [2]. Interest- 
ingly the increased local blood flow is not matched by an in- 
crease in oxygen consumption, but rather an activation of gly- 
colysis, thus the local oxygen tension increases. It is conceivable 
that the increased NO level, resulting from functional activa- 
tion and causing the increased blood flow, may also locally 
inhibit cytochrome oxidase and thus be responsible for depress- 
ing local oxygen consumption during functional activation. 
5. Cytotoxicity 
NO release from a whole range of cells is thought to be 
involved in killing pathogens [1,3,36]. Neutrophils, platelets 
and endothelial cells, which express the constitutive form of N O 
synthase, can acutely produce NO in response to activation, 
which may be involved in killing pathogens. Endotoxins and/or 
cytokines can induce the expression of the inducible form of 
NO synthase in macrophages and cells within virtually every 
tissue in the body. This response has been suggested to act as 
a kind of primitive immune response, whereby the induced NO 
production kills pathogens locally. Activated macrophages can 
kill bacteria, tumour cells, and a variety of other pathogens; 
and one of the cytotoxic agents is thought to be NO. The 
mechanism of cytotoxicity of NO is unclear, but is thought o 
involve damage to: mitochondrial complexes I and II, mito- 
chondrial aconitase, glyceraldehyde-3-phosphate dehydroge- 
nase, ribonucleotide r ductase, and DNA [1]. An acute inhibi- 
tion of mitochondrial cytochrome oxidase or bacterial oxidases 
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might also contribute to the killing of pathogens. The cyto- 
chrome oxidase activity of Paracoccus denitrif icans has been 
found to be sensitive to NO, and in some conditions cellular 
respiration is inhibited by the NO generated by the cells them- 
selves [8]. 
Expression of the inducible form of NO synthase is part of 
the signal transduction mechanism by which cytokines and 
bacterial endotoxins induce inflammatory responses [3,5,36]. 
Inflammatory responses probably mediated in part by NO in- 
clude w~sodilation, adhesion of leucocytes, microvascular per- 
meation, and killing of pathogens. An excessive or chronic 
inflammatory response has been implicated as being pathologi- 
cal in a large range of disease processes, including neurodegen- 
erative diseases. High levels of NO will damage or kill many cell 
type; thus excess NO has been suggested to be involved in 
pathology of sepsis, endotoxemia, arthritis, asthma, diabetes, 
multiple sclerosis, Alzheimer's disease, Parkinson's disease, 
AIDS dementia, and ischaemic damage to brain and heart 
[I 5,361. 
Cultured vascular smooth muscle cells activated by inter- 
leukin-lfl produce 0.5 yM NO at their surface [23]. Cultured 
astrocytes activated by endotoxin and interferon- 7 have been 
measured to produce 0.4 1.0]~M NO in dilute incubations [10]. 
Thus the levels of NO produced in response to cytokines and 
endotoxin appear sufficient o inhibit cytochrome oxidase. And 
indeed in the activated astrocytes it was shown that cytochrome 
oxidase was reversibly inhibited by the NO produced, resulting 
in a strong inhibition of respiration [10]. These cells also have 
an irreversible inhibition of cytochrome oxidase and complex 
I due to long-term exposure to NO [37]. The irreversible dam- 
age might be a consequence of reversible inhibition of cyto- 
chrome oxidase, since inhibition of cytochrome oxidase is well 
known to greatly stimulate the production of reactive oxygen 
intermediates IH20: and O_,D from the mitochondrial respira- 
tory chain, and these metabolites may damage many cellular 
systems. This might be a general mechanism for converting 
from reversible inhibition by NO to irreversible damage. It has 
been proposed that NO directly damages iron sulphur centres 
in the mitochondrial electron transport chain [1], but it now 
appears that these centres are relatively insensitive to direct 
attack by NO [38]. 
Since induction of the inducible form of NO synthase by 
cytokines and/or endotoxin causes production of NO to levels 
sufficient o substantially inhibit cellular respiration via cyto- 
chrome oxidase [10], it seems likely that this inhibition mediates 
a general metabolic suppression in conditions where NO syn- 
thase is known to be induced, such as sepsis, inflammatory 
disease, neurodegenerative disease, and post-ischaemia (Fig. 1 ). 
This might explain, for example, the inhibition of glucose and 
protein synthesis in cells expressing the inducible form of NO 
synthase [39], or the inhibition of contractile function in heart 
following exposure to endotoxin [40]. 
6. Conclusion 
NO almost certainly acts on cells by a variety of different 
effector systems. There is now growing evidence that one of 
these effector systems is cytochrome oxidase. 
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